The emerging role of new biomarkers of congestion in heart failure

Hesham R. Omar, Maya Guglin


The prevalence of heart failure (HF) continues to grow rapidly and is projected to rise by 46% by 2030 (1). High morbidity and mortality in patients with this condition creates a need for reliable and affordable non-invasive monitoring tools that can guide the therapy and predict outcomes. In a recent paper by Arrigo and colleagues (2), authors investigate a novel biomarker, Soluble CD146, and compare it with a well-established natriuretic peptide: NT-proBNP. In order to better understand the value of this study, we’ll briefly summarize the history, biology, and significance of natriuretic peptides and briefly review other biomarkers of congestion in HF.